Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitors and Chemoradiotherapy as Adjuvant Regimen for Resected pN3 Gastric or GEJ Adenocarcinoma
NCT04997837Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2021
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Fudan University. Primary endpoint: Disease-Free Survival at 3 years. Started Jul 2021; status: recruiting.
02
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04997837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04997837.